A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NT-0796 as an Adjunct to a Reduced Calorie Diet and Increased Physical Activity in Obese Participants With/Without Type 2 Diabetes
Latest Information Update: 21 Jul 2025
At a glance
- Drugs NT-0796 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Nodthera
Most Recent Events
- 21 Jul 2025 New trial record